Pneumologie 1999; 53(11): 521-529
DOI: 10.1055/s-1999-9244
ÜBERSICHT
Georg Thieme Verlag Stuttgart ·New York

Fluorchinolone zur Therapie von Atemwegsinfektionen[1]

Pharmakologisch-toxikologische AspekteR. Stahlmann
  • Institut für Klinische Pharmakologie und Toxikologie, Abt. Toxikologie, Freie Universität Berlin, Garystraße 5, Berlin
Further Information

Publication History

Publication Date:
31 December 1999 (online)

Also available at
 

Fluorchinolone werden in zunehmendem Maße zur Therapie bakterieller Infektionen der Atemwege eingesetzt. Der Grund für diese Tendenz liegt in der Entwicklung neuer Chinolone, die eine gute bis sehr gute Aktivität gegen Pneumokokken und andere häufige Erreger von Atemwegsinfektionen aufweisen. Dadurch unterscheiden sie sich von den seit langem bekannten Chinolonen wie Ofloxacin und Ciprofloxacin, deren Stärke vor allem im gramnegativen Bereich des bakteriellen Spektrums liegt.

1 Herrn Prof. Dr. H. Lode zum 60. Geburtstag gewidmet

Literatur

  • 1 Naber K G, Adam D. Classification of fluoroquinolones.  Int J Antimicrob Agents. 1998;  10 255-257
    PubMedSearch in Google Scholar
  • 2 Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, Minami S, Watanabe Y, Narita H. In vitro and in vivo antimicrobial activities of T-3811 ME, a novel des-F(6)-quinolone.  Antimicrob Agents Chemother. 1999;  43 1077-1084
    PubMedSearch in Google Scholar
  • 3 MacGowan A P, Bowker K E, Wootton M, Holt H A. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.  Antimicrob Agents Chemother. 1999;  43 1560-1564
    PubMedSearch in Google Scholar
  • 4 Drusano G L, Johnson D E, Rosen M, Standiford H C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.  Antimicrob Agents Chemother. 1993;  37 483-490
    CrossrefPubMedSearch in Google Scholar
  • 5 Forrest A, Ballow C H, Nix D E, Birmingham M C, Schentag J J. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.  Antimicrob Agents Chemother. 1993a;  37 1065-1072
    PubMedSearch in Google Scholar
  • 6 Forrest A, Nix D E, Ballow C H, Goss T F, Birmingham M C, Schentag J J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.  Antimicrob Agents Chemother. 1993b;  37 1073-1081
    CrossrefPubMedSearch in Google Scholar
  • 7 Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones.  Clin Infect Dis. 1998;  27 33-39
    PubMedSearch in Google Scholar
  • 8 Schüler P, Zemper K, Borner K, Koeppe P, Schaberg T, Lode H. Penetration of sparfloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes.  Eur Respir J. 1997;  10 1130-1136
    CrossrefPubMedSearch in Google Scholar
  • 9 Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy.  Clin Drug Invest. 1999;  17 365-387
    PubMedSearch in Google Scholar
  • 10 Lode H, Höffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P, Sievers B, Reimnitz D, Borner K, Koeppe P. Comparative pharmacokinetics of new quinolones.  Drug. 1987a;  34 (Suppl 1) 21-25
    PubMedSearch in Google Scholar
  • 11 Lode H, Höffken G, Olschewski P, Sievers B, Kirch A, Borner K, Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration.  Antimicrob Agents Chemother. 1987b;  31 1338-1342
    PubMedSearch in Google Scholar
  • 12 Davis R, Bryson H M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.  Drugs. 1994;  47 677-700
    PubMedSearch in Google Scholar
  • 13 Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review.  J Antimicrob Chemother. 1996;  37 (Suppl A) 27-39
    PubMedSearch in Google Scholar
  • 14 Efthymiopoulos C, Bramer S L, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.  Clin Pharmacokinet. 1997a;  33 (Suppl 1) 1-8
    PubMedSearch in Google Scholar
  • 15 Efthymiopoulos C, Bramer S L, Maroli A, Blum B. Theophylline and warfarin interaction studies with grepafloxacin.  Clin Pharmacokin. 1997b;  33 (Suppl 1) 39-46
    PubMedSearch in Google Scholar
  • 16 Barman Balfour J A, Wiseman L R. Moxifloxacin.  Drugs. 1999;  57 363-373
    PubMedSearch in Google Scholar
  • 17 Stass H. Metabolism and excretion of moxifloxacin.  Drugs. 1999b;  58 (Suppl) 16-17
    PubMedSearch in Google Scholar
  • 18 Chodosh S, McCarty J, Farkas S, Drehobl M, Tosiello R, Shan M, Aneiro L, Kowalsky S. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.  Clin Infect Dis. 1999a;  27 722-729
    PubMedSearch in Google Scholar
  • 19 Chodosh S, Schreurs A, Siami G, Barkman H W, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.  Clin Infect Dis. 1999b;  27 730-738
    PubMedSearch in Google Scholar
  • 20 Reinert R R, Queck A, Kaufhold A, Kresken M, Lutticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992 - 1994.  Clin Infect Dis. 1995;  21 1398-1401
    PubMedSearch in Google Scholar
  • 21 Momme¿ja-Marin H, Carbon C. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections.  Drugs. 1999;  57 851-853
    PubMedSearch in Google Scholar
  • 22 Chen D K, McGeer A, Azavedo J C, Low D E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.  New Engl J Med. 1999;  341 233-239
    CrossrefPubMedSearch in Google Scholar
  • 23 Stahlmann R, Lode H. Nebenwirkungen der neueren Fluorchinolone.  Arzneimitteltherapie. 1998a;  16/12 385-394
    PubMedSearch in Google Scholar
  • 24 Stahlmann R, Lode H. Safety overview. Toxicity, adverse effects, and drug interactions. In: Andriole VT (Hrsg) The Quinolones. San Diego et al; Academic Press 1998c: 369-415
    Search in Google Scholar
  • 25 Langan C E, Cranfield R, Breisch S, Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.  J Antimicrob Chemother. 1997;  40 (Suppl A) 63-72
    CrossrefPubMedSearch in Google Scholar
  • 26 Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.  Antimicrob Agents Chemother. 1998;  42 114-120
    PubMedSearch in Google Scholar
  • 27 Shah P M, Maesen F P, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.  J Antimicrob Chemother. 1999;  43 529-539
    CrossrefPubMedSearch in Google Scholar
  • 28 Höffken G, Meyer H P, Sprenger K, Verhoef L, . The CAP 1 Study Group . Efficacy and safety of moxifloxacin (MFX) vs. clarithromycin (CLR) for the treatment of community-acquired pneumonia (CAP).  J Antimicrob Chemother. 1999;  44 (Suppl A) 390
    PubMedSearch in Google Scholar
  • 29 Stahlmann R, Lode H. Toxicity of quinolones.  Drugs. 1999;  58 (Suppl 2) 39-44
    PubMedSearch in Google Scholar
  • 30 Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and children.  Inf Dis Clin Pract. 1994;  3 (Suppl 3) 168-176
    PubMedSearch in Google Scholar
  • 31 Bowie W R, Willetts V, Jewesson P J. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.  Antimicrob Agents Chemother. 1989;  33 1778-1782
    PubMedSearch in Google Scholar
  • 32 Vincent J, Agin M, Laboy-Goral L, Hunt T, Carlson J, Apseloff G, Kuye O. Effect of dosing with food and bedtime dosing on the incidence of dizziness/lightheadedness with trovafloxacin in young, healthy, female subjects. ICAAC 1998 Poster A-086
    Search in Google Scholar
  • 33 NN 1999. Trovafloxacin.  Z Chemother 1999 20: 30-31 (oder www.zct-berlin.de, Neueinführungen, Trovafloxacin)
    Search in Google Scholar
  • 34 Stahlmann R, Lode H. Safety of quinolones.  The Lancet. 1998b;  352/9136 1313 (Letter)
    PubMedSearch in Google Scholar
  • 35 Carrasco J M, Gacia B, Andujar C, Garrote F, Juana P, Bermejo T. Tendinitis associated with ciprofloxacin.  Ann Pharmacother. 1997;  31 120 (Letter)
    PubMedSearch in Google Scholar
  • 36 Kahn M F, Hayem G. Tendons and fluoroquinolones - unresolved issues.  Rev Rhum (Engl Ed). 1997;  64 437-439
    PubMedSearch in Google Scholar
  • 37 Shakibaei M, Pfister K, Schwabe R, Stahlmann R. Effects of ofloxacin on the ultrastructure of Achilles tendon in rats.  Drugs. 1999;  58 (Suppl 2) 390-392
    PubMedSearch in Google Scholar
  • 38 Lode H. Drug interactions with quinolones.  Rev Infect Dis. 1988;  10 (Suppl 1) 132-136
    PubMedSearch in Google Scholar
  • 39 Janknegt R. Drug interactions with quinolones.  J Antimicrob Chemother. 1990;  26 (Suppl D) 7-29
    PubMedSearch in Google Scholar
  • 40 Stahlmann R, Deppermann K-M, Schulz-Schalge T, Lode H. Klinisch relevante Arzneimittel-Interaktionen während einer Behandlung mit Chinolonen.  Chemother J. 1992;  1/1 7-10
    PubMedSearch in Google Scholar
  • 41 Nix D E. Drug-drug interactions with fluoroquinolone antimicrobial agents. In: Hooper, DC, Wolfson, JS (eds) Quinolone Antimicrobial Agents. Washington; Am Soc Microbiol 1993: 245-258
    Search in Google Scholar
  • 42 Höffken G, Borner K, Glatzel P D, Koeppe P, Lode H. Reduced internal absorption of ciprofloxacin in the presence of antacids.  Eur J Clin Microbiol. 1985;  4 345
    PubMedSearch in Google Scholar
  • 43 Höffken G, Lode H, Wiley R, Glatzel T D, Sievers D, Olschewski T, Borner K, Koeppe P. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake.  Rev Infect Dis. 1988;  10 (Suppl 1) 138-139
    PubMedSearch in Google Scholar
  • 44 Deppermann K M, Lode H. Fluoroquinolones. Interaction profile of central absorption.  Drugs. 1993;  45 (Suppl 3) 65-72
    PubMedSearch in Google Scholar
  • 45 Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability.  Clin Pharmacol Ther. 1993;  53 292-297
    PubMedSearch in Google Scholar
  • 46 Garrelts J C, Godley P J, Peterie J D, Gerlach E H, Yakshe C C. Sucralfate significantly reduces ciprofloxacin concentrations in serum.  Antimicrob Agents Chemother. 1990;  34 931-933
    PubMedSearch in Google Scholar
  • 47 Kawai Y, Matsubayashi K, Hakusui H. Interactions of quinolones with metal cations in aqueous solution.  Chem Pharm Bull. 1996;  44 1425-1430
    PubMedSearch in Google Scholar
  • 48 Stass H, Wandel C. No significant interaction between oral moxifloxacin (MOX) and calcium supplements (CAS) in healthy volunteers (HV).  J Antimicrob Chemother. 1999;  44 (Suppl A) 416
    CrossrefPubMedSearch in Google Scholar
  • 49 Neuvonen P J, Kivistö K T, Lehto P. Interference of dairy products with the absorption of ciprofloxacin.  Clin Pharmacol Ther. 1991;  50 498-502
    PubMedSearch in Google Scholar
  • 50 Stass H. Absorption and bioavailability of moxifloxacin.  Drugs. 1999a;  58 (Suppl) 14-15
    PubMedSearch in Google Scholar
  • 51 Polk R E, Healy D P, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.  Antimicrob Agents Chemother. 1989;  33 1841-1844
    PubMedSearch in Google Scholar
  • 52 Lomaestro B M, Bailie G R. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin.  Antimicrob Agents Chemother. 1991;  35 1004-1007
    PubMedSearch in Google Scholar
  • 53 Palu¿ G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. Quinolone binding to DNA is mediated by magnesium ions.  Proc Natl Acad Sci USA. 1992;  89 9671-9675
    PubMedSearch in Google Scholar
  • 54 Wijnands W J, Herwaarden C L, Vree T B. Enoxacin raises plasma theophylline concentrations.  The Lancet. 1984;  2 108-109
    PubMedSearch in Google Scholar
  • 55 Maesen F PV, Teengs J P, Baur C, Davies B I. Quinolones and raised plasma concentrations of theophylline.  Lancet. 1984;  2 530
    PubMedSearch in Google Scholar
  • 56 Davies B I, Maesen F PV, Teengs J P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.  J Antimicrob Chemother. 1984;  14 (Suppl C) 83-89
    PubMedSearch in Google Scholar
  • 57 Wijnands W J, Vree T B, Herwaarden C L. The influence of quinolone derivates on theophylline clearance.  Br J clin Pharmacol. 1986;  22 677-683
    PubMedSearch in Google Scholar
  • 58 Stille W, Harder S, Mieke S, Beer C, Shah P M, Frech K, Staib A H. Decrease of caffeine elimination in man during co-administration of 4-quinolones.  J Antimicrob Chemother. 1987;  20 729-734
    PubMedSearch in Google Scholar
  • 59 Healy D P, Polk R E, Kanawati L, Rock D T, Mooney M L. Interaction between oral ciprofloxacin and caffeine in normal volunteers.  Antimicrob Agents Chemother. 1989;  33 474-478
    PubMedSearch in Google Scholar

1 Herrn Prof. Dr. H. Lode zum 60. Geburtstag gewidmet

Ralf Stahlmann

Institut für Klinische Pharmakologie und Toxikologie

Abt. Toxikologie

Freie Universität Berlin

Garystraße 5

D-14195 Berlin